- €527.47m
- €532.72m
- €100.20m
- 95
- 12
- 81
- 71
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 26.51 | ||
| PEG Ratio (f) | 1.42 | ||
| EPS Growth (f) | 23.02% | ||
| Dividend Yield (f) | 1.78% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.62 | ||
| Price to Tang. Book | 16.71 | ||
| Price to Free Cashflow | 35.91 | ||
| Price to Sales | 4.95 | ||
| EV to EBITDA | 19.12 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 29.52% | ||
| Return on Equity | 28.01% | ||
| Operating Margin | 23.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 53.62 | 56.45 | 68.11 | 82.72 | 100.2 | 113.13 | 128 | 16.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -1.31 | +71.19 | -3.7 | +8.21 | -14.24 | +33.96 | +20.5 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pharmanutra SpA is an Italy-based company engaged in the healthcare industry. The Company develops nutraceutical products and medical devices. It focuses on studying and producing formulations that are backed up in scientific research. It is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The Company offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- January 1st, 1970
- Public Since
- July 18th, 2017
- No. of Employees
- 112
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Borsa Italiana- Shares in Issue
- 9,607,921
- Address
- Via delle Lenze n. 216/B, PISA, 56122
- Web
- https://www.pharmanutra.it/
- Phone
- Auditors
- BDO Italia S.p.A.
Upcoming Events for PHN
Similar to PHN
Friulchem SpA
Borsa Italiana
Recordati Industria Chimica E Farmaceutica SpA
Borsa Italiana
Shedir Pharma Srl Unipersonale
Borsa Italiana
FAQ
As of Today at 22:38 UTC, shares in Pharmanutra SpA are trading at €54.90. This share price information is delayed by 15 minutes.
Shares in Pharmanutra SpA last closed at €54.90 and the price had moved by +15.46% over the past 365 days. In terms of relative price strength the Pharmanutra SpA share price has underperformed the FTSE Global All Cap Index by -0.39% over the past year.
The overall consensus recommendation for Pharmanutra SpA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Pharmanutra SpA dividend yield is 1.55% based on the trailing twelve month period.
Last year, Pharmanutra SpA paid a total dividend of €0.85, and it currently has a trailing dividend yield of 1.55%. We do not have any data on when Pharmanutra SpA is to next pay dividends.
We do not have data on when Pharmanutra SpA is to next pay dividends. The historic dividend yield on Pharmanutra SpA shares is currently 1.55%.
To buy shares in Pharmanutra SpA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €54.90, shares in Pharmanutra SpA had a market capitalisation of €527.47m.
Here are the trading details for Pharmanutra SpA:
- Country of listing: Italy
- Exchange: MIL
- Ticker Symbol: PHN
Based on an overall assessment of its quality, value and momentum Pharmanutra SpA is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pharmanutra SpA is €81.30. That is 48.09% above the last closing price of €54.90.
Analysts covering Pharmanutra SpA currently have a consensus Earnings Per Share (EPS) forecast of €1.79 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharmanutra SpA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -1.82%.
As of the last closing price of €54.90, shares in Pharmanutra SpA were trading +1.91% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pharmanutra SpA PE ratio based on its reported earnings over the past 12 months is 26.51. The shares last closed at €54.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Pharmanutra SpA's directors